Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma

The purpose of this study is to determine whether combining Loncastuximab Tesirine with Epcoritamab is tolerable and effective for reducing and/or eliminating lymphoma cells in the body.

Trial Details

NCT ID
NCT06919939
Phase
PHASE2
Sponsor
University of Miami
Status
RECRUITING
Cancer Type
Hodgkin Lymphoma Lymphoma
Interventions
  • Epcoritamab
  • Loncastuximab Tesirine
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

  • Men and women aged 18 years or older at the time of signing informed consent.
  • Able and willing to sign the informed consent form (ICF).
  • Ability to comply with the trial protocol.
  • Relapsed/refractory (r/r) large B-cell lymphoma (LBCL) as determined by the local hematopathology laboratory from the following diagnoses by 2016 W…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hodgkin Lymphoma Lymphoma Trials on Trialify →